Cipla Global Ltd.: Generics versus Drug Discovery
8,00 $ – 50,00 $
CASE STUDY. Thanks to India’s process patent regime (1970–2005), Dr. Yusuf Hamied, the company’s chairman, managed to catapult the company to its position as a leading generics manufacturer.
